Paper
- Alzforum Recommends
Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011 Jun;69(6):940-53. Epub 2011 Apr 6 PubMed.
Recommends
Please login to recommend the paper.
Comments
Link Medicine Corporation
This paper by the Krainc group confirms previous work by our group and others, and provides a nice insight into the possible mechanisms by which dysregulation or mutation in the glucocerebrosidase (GBA) protein can lead to synucleinopathies.
The cell work in this paper focused mainly on knockdown of GBA, showing that loss of the protein and its enzyme activity caused a decrease in lysosomal degradation of long-lived proteins and therefore an increase in synuclein. We also tried to inhibit the enzymatic function (rather than protein levels) with conduritol B epoxide (CBE) in cells, and did not observe an increase in synuclein, but our CBE treatment was shorter than their knockdown, which probably explains that result. One other group has previously shown that CBE can cause α-synuclein accumulation.
Our Annals of Neurology paper (Cullen et al., 2011) instead focused on cell models of expression/overexpression of mutant GBA. We showed that expression of mutant but not wild-type GBA caused an increase in synuclein levels as measured by sensitive ELISA. This occurred without any dominant-negative effect of the mutants on endogenous enzyme function. What was also very interesting was that in one cell line, the wild-type GBA had the opposite effect; i.e., it could lower synuclein levels.
Obviously, a therapeutic implication of the above finding would be that overexpression of GBA by viral vector or otherwise might be beneficial in synucleinopathies.
Krainc et al. in their discussion implied that another therapeutic strategy would be to more efficiently chaperone GBA to the lysosome. We found in our study that the GBA chaperone, isofagomine, did have a trend towards reducing synuclein. Perhaps a different dose or treatment time would have been even more effective. This strategy is definitely worth pursuing in further studies.
Krainc also nicely showed that knockdown of GBA caused an inhibition of lysosomal degradation of long-lived proteins. Although they did not mention it much, this degradation typically occurs by macroautophagy. We found that the autophagy inducer rapamycin ameliorated the increase in synuclein noted with GBA overexpression, indicating that this may be a nice therapeutic target to pursue also.
Both papers examined synuclein accumulation in animal models of GD with mutations in GBA. The findings converged nicely and showed that dysregulation of GBA is associated with an accumulation of synuclein in various brain regions. Our group also showed that the GBA mutant mice had a similar immunohistochemical pathology as another mouse model, that of the Cathepsin D knockout, which imitates a rare but informative lysosomal storage disorder, CLN10 (see also Cullen et al., 2009). Krainc’s examination of human brain specimens is a nice extension of the mouse work.
All in all, both papers are complementary and point to a very important interplay between GBA and synuclein metabolism. Further work on this biochemical interplay will shed new light on the genetic intersection of GBA with synucleinopathy disorders, and hopefully on new and fruitful therapeutic approaches.
References:
Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P, Woulfe J, Feany MB, Myllykangas L, Schlossmacher MG, Tyynelä J. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain. 2009;2:5. PubMed.
View all comments by Valerie CullenUniversity of Oxford
This certainly is an impressive amount of work focusing thoroughly on the mechanistic link between glucocerebrosidase (GCase), glucocerebroside (GlcCer), and α-synuclein by robustly combining, in vitro, Gaucher's disease (GD), animal model, and human postmortem data. Mazzulli et al. have carried out a number of elegant in vitro assays to show that GlcCer selectively stabilizes the formation of soluble α-synuclein oligomeric intermediates on the pathway toward amyloid fibrils. These findings are corroborated by the GD mouse model, showing increased levels of putative oligomers by size exclusion chromatography (i.e., 120-70 Å- and 51-44 Å-sized species), whereas only monomers were found in control mice. Importantly, when analyzing human postmortem cortical samples from GD patients with atypical Parkinson’s disease or dementia with Lewy bodies (DLB), they observed increased oligomeric α-synuclein eluting above 36 Å and migrating at 22, 44, and 75 kDa by SDS-PAGE.
An interesting finding is that GCase function is preferentially related to α-synuclein (does not affect tau). This is also supported by pathological findings from those carrying GCase gene (GBA) mutations, who tend to show “purer “LB pathology without concomitant Alzheimer’s disease pathology (Clark et al., 2009). Additionally, in contrast to some preliminary data suggesting that GBA mutation carriers may have a more augmented LB pathology (Neumann et al., 2009), we recently showed that these carriers do not have higher age- and dementia-adjusted LB densities compared to sporadic PD cases (Parkkinen et al., 2011). This is in line with the findings by Mazzulli et al. suggesting that the GBA mutations may enhance the formation of α-synuclein oligomers that could kill the cell prior to any inclusion (i.e., LB) formation.
In regard to the authors’ in vitro findings, the assays are quite strongly focusing on GCase knockdown models, which I’m not sure are the correct models, as Cullen and colleagues (Cullen et al., 2011) have shown that overexpression of mutant GBA proteins in vitro does indeed promote the accumulation of α-synuclein, but this appears to be independent of GCase activity (not compromised). In addition, chemical inhibition of GCase in their hands did not elevate the concentration of α-synuclein, in contrast to earlier work (Manning-Bog et al., 2009).
In addition, using the same 4L/PS-NA mouse model (in an identical time point of 12 weeks), Cullen et al. did not note any significant α-synuclein (either soluble or insoluble) accumulation at the biochemical level. Their neuropathological analysis did, however, reveal neuronal spheroids and some enhancement of cytoplasmic α-synuclein immunoreactivity in the frontal cortex, corpus callosum, and cerebellum. However, the punctate pattern Mazzulli et al. describe with immunofluorescence is novel.
Although GBA mutations are the most common genetic risk factor for PD, most PD patients do not harbor these mutations, and Mazzulli et al. suggest a very interesting theory for how GCase links to α-synuclein levels in these patients: The accumulation of oligomeric α-synuclein could block endoplasmic reticulum-Golgi trafficking of GCase, preventing its normal maturation, then a decrease in lysosomal GCase leads to further accumulation of GlcCer and the stabilization of oligomeric α-synuclein. This positive feedback, self-propagating loop provides a potential therapeutic target for sporadic PD. The only problem with this “loss-of-function” theory is that it does not explain why the majority of homozygous Gaucher’s patients, and even heterozygotes (all showing lower levels of GCase), do not develop synucleinopathy or parkinsonism.
References:
Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, Vonsattel JP, Fahn S, Mayeux R, Honig LS, Marder K. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol. 2009 May;66(5):578-83. PubMed.
Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009 Jul;132(Pt 7):1783-94. PubMed.
Parkkinen L, Neumann J, O'Sullivan SS, Holton JL, Revesz T, Hardy J, Lees AJ. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Mol Genet Metab. 2011 Aug;103(4):410-2. PubMed.
Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011 Jun;69(6):940-53. Epub 2011 Apr 6 PubMed.
Manning-Boğ AB, Schüle B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology. 2009 Nov;30(6):1127-32. PubMed.
View all comments by Laura ParkkinenUniversity of California, San Diego
Mazzulli et al. describe an incredibly important study linking the activity of the lysosomal enzyme, glucocerebrosidase, with the accumulation and fibrilization of α-synuclein. Their study extends previous research into the correlation of glucocerebrosidase mutations observed in Gaucher’s disease patients with an increased incidence of Parkinson’s disease in these patients. Decreased localization of glucocerebrosidase to the lysosome leads to an accumulation of glucocerebroside (the substrate of glucocerebrosidase), and thus leads to an accumulation of α-synuclein. The authors showed that the accumulating glucocerebroside polymerizes into tubules that may act as a scaffold for the polymerization of α-synuclein, leading to increased fibrillization of the latter. The authors further show that expression and accumulation of α-synuclein directly affects the endogenous localization of glucocerebrosidase, thus providing a positive feedback loop for the further accumulation of α-synuclein, and finally fibrillization.
Examination of patients with type 2 or 3 neuronopathic Gaucher’s disease showed an increased accumulation of α-synuclein in the CNS even at very young ages (The authors’ mouse model of Gaucher’s disease may be a good model of idiopathic Parkinson’s disease. Glucocerebrosidase knockout mice die shortly after birth due to defects in the epithelium. This newer glucocerebrosidase mutant developed by Grabowski’s lab (Xu et al., 2011) shows significantly reduced levels of glucocerebrosidase activity and thus delayed onset of pathology.
The authors suggest that a method of providing more glucocerebrosidase to the lysosomes of neurons may be an effective therapeutic avenue for Parkinson’s disease, as this would theoretically reduce the accumulation of α-synuclein as well as reduce the ability of α-synuclein to polymerize. Intravenous infusion of in vitro glycosylated glucocerebrosidase is an effective therapy for Gaucher’s disease patients (e.g., Cerezyme, Genzyme Corporation); however, the enzyme is not trafficked from the blood to the CNS, due to the presence of the blood-brain barrier. We showed a novel method for the delivery of glucocerebrosidase from the periphery to the CNS and to neuronal lysosomes (Spencer and Verma, 2007). This, too, may be an attractive therapeutic approach. Additionally, some researchers have investigated the use of chemical or protein chaperones that enhance the transport of glucocerebrosidase from the ER to the lysosomes. These would appear to be attractive for PD, too.
References:
Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. 2011 Apr;102(4):436-47. Epub 2010 Dec 31 PubMed.
Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7594-9. PubMed.
View all comments by Brian SpencerUnique clinical observations and elegant genetic research have established that approximately 10-12 percent of people with Parkinson’s have a mutation in one copy of a gene encoding the lysosomal enzyme glucocerebrosidase, or GBA1 (Sidransky et al., 2009). Today, mutations in GBA1 are considered the most common known genetic risk factor for the synucleinopathies, PD and DLB.
Despite the wealth of clinical and genetic evidence supporting the association between GBA1 and α-synuclein accumulation, the underlying mechanisms by which GBA1 mutations can lead to α-synuclein misprocessing are not understood.
A GBA1 loss-of-function hypothesis and a mutant, toxic gain-of-function hypothesis have emerged to explain the effects of GBA1 on α-synuclein processing. Importantly, these hypotheses are not mutually exclusive, and are supported by clinical and genetic evidence. (For more details see, Velayati et al., 2010).
Recent Data: Gain of Function Versus Loss of Function?
In recent months, several articles have shed more light into this complex interaction. In collaboration with Michael Schlossmacher at the University of Ottawa, we demonstrated that overexpression of mutant forms of GBA1 can increase α-synuclein levels in a dose- and time-dependent manner (Cullen et al., 2011). Furthermore, we showed that increasing GBA1 activity reduces the levels of α-synuclein in a cell-specific manner, suggesting the therapeutic potential of modulating this pathway in synucleinopathies.
Now, the group led by Dimitri Krainc at Massachusetts General Hospital shows that reduction in GBA1 activity can increase α-synuclein toxicity by stabilizing oligomeric intermediates, possibly through the accumulation of a GBA1 substrate (GlcCer). Interestingly, these authors also show that elevated α-synuclein levels impair GBA1 function in the lysosome, suggesting a vicious cycle whereby α-synuclein accumulation leads to decreased GBA1 activity, which in turn incites more α-synuclein accumulation.
The current evidence suggests that both GBA1 gain- and loss-of-function mechanisms conspire to promote aberrant α-synuclein processing. Mutations in GBA1 appear to be sufficient to initiate α-synuclein misfolding, while a decrease in GBA1 activity (regardless of mutations) seems to accelerate its misprocessing. Importantly, elevation of α-synuclein seems to prevent normal trafficking of GBA1 to the lysosome, thereby promoting more α-synuclein accumulation. Together, these mechanisms would support increasing GBA1 activity in the lysosomes as a therapeutic approach.
In summary, GBA1-mediated pathways have emerged as attractive targets for Gaucher's-related and sporadic synucleinopathies and, possibly, for other neurodegenerative diseases. These recent reports by Cullen et al., and this paper by Mazzulli et al., are important stepping stones in unveiling the complex complot between GBA1 and α-synuclein. As the worldwide pioneers in treating Gaucher's disease, we (at Genzyme) have been actively pursuing this line of research, and we hope to provide more answers in the near future.
References:
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61. PubMed.
Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010 May;10(3):190-8. PubMed.
Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011 Jun;69(6):940-53. Epub 2011 Apr 6 PubMed.
View all comments by S Pablo SardiMake a Comment
To make a comment you must login or register.